重组人α-2b干扰素凝胶联合微波治疗妊娠尖锐湿疣保胎者的疗效及预后  

The clinical efficacy and prognosis of recombinant human interferon α-2b combined with microwave in treatment for pregnant women with condyloma acuminate

作　　者：陈访梅 

机构地区：[1]广东省惠州市皮肤病防治研究所,惠州516008

出　　处：《临床医学》2015年第5期17-19,共3页Clinical Medicine

摘　　要：目的探讨重组人α-2b干扰素凝胶联合微波治疗妊娠尖锐湿疣保胎者的临床疗效及预后。方法将60例妊娠合并尖锐湿疣保胎者随机分为对照组和治疗组,每组30例。对照组单纯予以微波治疗,治疗组予以微波联合重组人α-2b干扰素凝胶外用治疗,对尖锐湿疣治疗效果及妊娠结局进行分析。结果治疗组治愈率83.3%(25/30),复发率36.7%(11/30);对照组治愈率46.7%(14/30),复发率73.3%(22/30),两组比较差异有统计学意义(χ2=7.177,P=0.007)。两组均未见影响分娩及新生儿HPV感染的病例发生。结论妊娠合并尖锐湿疣保胎者应用重组人α-2b干扰素凝胶联合微波疗效确切,预防复发效果显著,有利于继续妊娠及正常分娩。Objective To evaluate the clinical efficacy and prognosis of condyloma acuminate in pregnant women treated by re- combinant human interferon α-2b combined with microwave. Methods Sixty cases of pregnant women with condyloma acuminate were selected and divided into control group and study group. The control group were treated by microwave treatment, and the cases in study group were treated with recombinant human interferon α-2b combined with microwave treatment. The clinical effects and outcomes of pregnancy were assessed after treatment between the two groups. Results The cure rate of study group as 83.3% （25/ 30）, which was significantly higher than that of control group; the recurrence rate of study group was 36. 7% （ 11/30）, which was obviously lower than that of control group （X^2 = 7. 177,P = 0. 007）. Conclusion Recombinant human interferon α-2b combined with microwave treatment is a safe and efficient treatment for condyloma acuminate in pregnant women; it can reduce the recurrence of condyloma acuminate and is benefit for continued gestation and normal delivery.

关 键 词：重组人Α-2B干扰素 微波治疗 尖锐湿疣 妊娠期 保胎 

分 类 号：R714.259[医药卫生—妇产科学]